
Neurogene Inc (NGNE) Stock Forecast & Price Target
Neurogene Inc (NGNE) Analyst Ratings
Bulls say
Neurogene Inc. is showing promise in its clinical-stage developments, particularly with NGN-401 for Rett syndrome, which has demonstrated durable improvements over 24 months in multiple clinical domains, outperforming peer data metrics. The company has significantly expanded its U.S. clinical footprint to 13 sites, enhancing its capacity for rapid patient enrollment while aligning with industry peers, indicating strong demand and support among caregivers. Moreover, the proprietary EXACTTM platform demonstrates a substantial advantage in brain expression compared to alternative technologies, underscoring Neurogene's competitive positioning in the biotechnology sector focused on rare neurological diseases.
Bears say
Neurogene Inc faces significant risks that could hinder its clinical development efforts and negatively impact its stock performance. Key concerns include potential delays in advancing its drug candidates through the clinical assessment process, specifically for NGN-401 in treating Rett syndrome, and the uncertainty surrounding the generation of favorable clinical data. Additionally, there is an underlying risk of long-term dilution and potential competitive disadvantages due to the anticipated need for amending regulatory filings based on delayed or inconclusive clinical results.
This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.
Neurogene Inc (NGNE) Analyst Forecast & Price Prediction
Start investing in Neurogene Inc (NGNE)
Order type
Buy in
Order amount
Est. shares
0 shares